Alivus Life Sciences has reported a strong performance for the second quarter of FY27, with revenue growing 16.0% year-on-year to ₹6,820 million. The company highlighted robust demand across key markets and contributions from recent product launches. EBITDA and PAT also saw significant year-on-year increases. The presentation outlines strategic growth levers including API business expansion, capacity enhancement, and R&D capabilities.
Alivus Life Sciences Reports Strong Q2 FY27 Performance
Alivus Life Sciences announced its financial and business highlights for the second quarter ended September 30, 2026 (Q2 FY27). The company achieved a significant 16.0% year-on-year (YoY) revenue growth, reaching ₹6,820 million. This growth was propelled by healthy demand across all key markets and contributions from recent product launches, with the non-GPL business momentum maintained and CDMO business seeing a meaningful pick-up.
Key Financial Highlights (Q2 FY27)
The company reported a Gross Profit of ₹4,391 million, a 29.5% increase YoY, with Gross Profit Margin at 64.4%. EBITDA stood at ₹2,851 million, marking a substantial 47.0% YoY growth and an EBITDA Margin of 41.8%. Profit After Tax (PAT) was ₹1,968 million, up by 51.3% YoY, with a Net Margin of 28.9%. The company generated a strong free cash flow of ₹2,702 million, leading to Cash and Cash Equivalents of ₹10,116 million as of September 30, 2026.
Segmental Performance Insights
The Generic API business saw strong growth of 11.0% YoY in Q2 FY27, driven by new product launches and healthy demand in existing portfolios across major markets like Europe, North America, Japan, LATAM, and ROW. The CDMO business demonstrated robust growth with a 32.3% quarter-on-quarter (QoQ) increase and 79.9% YoY growth, attributed to strong traction in existing projects and recent launches. The non-GPL business now contributes 79% of the company’s total revenues, while GPL business contributed 21% in Q2 FY27.
Market and Therapeutic Area Mix
Regulated markets continued to be a significant contributor, accounting for 85% of Q2FY27 revenues, driven by broad-based growth and a favorable product mix. Chronic therapies remained a key growth driver, representing 67% of Q2FY27 revenues.
R&D Capabilities and Infrastructure
Alivus Life Sciences reported filing 630 DMFs and CEPs across major markets. The company’s R&D efforts include the addition of 2 synthetic small molecules to its development grid and progress in its HP API portfolio with a Total Addressable Market (TAM) of approximately $86 billion. The iron complexes portfolio also shows progression with regulatory filing completed for one iron compound.
Future Strategy and Capacity Expansion
The company’s strategy focuses on growing its Gx API business through new product launches and geographical expansion. Capacity expansion is planned through greenfield and brownfield projects in Solapur, Ankleshwar, and Dahej, with significant additions aimed at scaling up manufacturing capabilities. The company is also enhancing its R&D setup for API development in flow chemistry, particle engineering, and complex technologies, alongside expanding its CDMO footprint.
Source: BSE
